• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SOX7 通过 DNMT3B/CYGB 轴抑制膀胱癌的恶性进展。

SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.

机构信息

Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China.

出版信息

Mol Biomed. 2024 Sep 4;5(1):36. doi: 10.1186/s43556-024-00198-8.

DOI:10.1186/s43556-024-00198-8
PMID:39227479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11371982/
Abstract

Bladder cancer (BCa) stands out as a highly prevalent malignant tumor affecting the urinary system. The Sex determining region Y-box protein family is recognized for its crucial role in BCa progression. However, the effect of Sex determining region Y-box 7 (SOX7) on BCa progression has not been fully elucidated. Herein, RNA-sequencing, western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF) and tissue microarray were utilized to assess SOX7 expression in vitro and in vivo. Additionally, SOX7 expression, prognosis, and SOX7 + cytoglobin (CYGB) score were analyzed using R software. In vitro and vivo experiments were performed with BCa cell lines to validate the effect of SOX7 knockdown and overexpression on the malignant progression of BCa. The results showed that SOX7 exhibits low expression in BCa. It functions in diverse capacities, inhibiting the proliferative, migratory, and invasive capabilities of BCa. In addition, the experimental database demonstrated that SOX7 binds to the promoter of DNA methyltransferase 3 beta (DNMT3B), leading to the transcriptional inhibition of DNMT3B. This subsequently results in a reduced methylation of CYGB promoter, ultimately inhibiting the tumor progression of BCa. SOX7 + CYGB scores were significantly linked to patient prognosis. In conclusion, SOX7 inhibits the malignant progression of BCa via the DNMT3B/CYGB axis. Additionally, the SOX7 + CYGB score is capable of predicting the prognostic outcomes of BCa patients. Therefore, SOX7 and CYGB may play an important role in the progression of bladder cancer, and they can be used as prognostic markers of bladder cancer patients.

摘要

膀胱癌（BCa）是一种常见的泌尿系统恶性肿瘤。性别决定区 Y 框蛋白家族在 BCa 进展中起着关键作用。然而，性别决定区 Y 框蛋白 7（SOX7）对 BCa 进展的影响尚未完全阐明。在此，我们利用 RNA 测序、western blot（WB）、免疫组织化学（IHC）、免疫荧光（IF）和组织微阵列技术，在体外和体内评估 SOX7 的表达。此外，还利用 R 软件分析 SOX7 表达、预后和 SOX7+细胞色素 b5（CYGB）评分。利用 BCa 细胞系进行体外和体内实验，验证 SOX7 敲低和过表达对 BCa 恶性进展的影响。结果表明，SOX7 在 BCa 中低表达。它具有多种功能，抑制 BCa 的增殖、迁移和侵袭能力。此外，实验数据库表明 SOX7 与 DNA 甲基转移酶 3β（DNMT3B）的启动子结合，导致 DNMT3B 的转录抑制。这进而导致 CYGB 启动子的甲基化减少，最终抑制 BCa 的肿瘤进展。SOX7+CYGB 评分与患者预后显著相关。总之，SOX7 通过 DNMT3B/CYGB 轴抑制 BCa 的恶性进展。此外，SOX7+CYGB 评分能够预测 BCa 患者的预后结果。因此，SOX7 和 CYGB 可能在膀胱癌的进展中发挥重要作用，并可作为膀胱癌患者的预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/a33f95d19148/43556_2024_198_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/3e3a18c194bc/43556_2024_198_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/f65f3bd7d03e/43556_2024_198_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/76bb77dd41e6/43556_2024_198_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/95b0918394a3/43556_2024_198_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/eee574deafaa/43556_2024_198_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/c1a2dabd042d/43556_2024_198_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/a33f95d19148/43556_2024_198_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/3e3a18c194bc/43556_2024_198_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/f65f3bd7d03e/43556_2024_198_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/76bb77dd41e6/43556_2024_198_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/95b0918394a3/43556_2024_198_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/eee574deafaa/43556_2024_198_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/c1a2dabd042d/43556_2024_198_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f51/11371982/a33f95d19148/43556_2024_198_Fig7_HTML.jpg

相似文献

1
SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.SOX7 通过 DNMT3B/CYGB 轴抑制膀胱癌的恶性进展。
Mol Biomed. 2024 Sep 4;5(1):36. doi: 10.1186/s43556-024-00198-8.
2
microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis.DNMT3B 调控的 microRNA-451a 启动子甲基化通过 EPHA2/PI3K/AKT 轴促进膀胱癌的发展。
BMC Cancer. 2020 Oct 21;20(1):1019. doi: 10.1186/s12885-020-07523-8.
3
Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.异甘草素抑制基底型肌层浸润性膀胱癌归因于其下调 SNHG1 和 DNMT3b。
BMC Cancer. 2024 Jun 15;24(1):737. doi: 10.1186/s12885-024-12490-5.
4
CCND1, NOP14 and DNMT3B are involved in miR-502-5p-mediated inhibition of cell migration and proliferation in bladder cancer.CCND1、NOP14 和 DNMT3B 参与 miR-502-5p 介导的膀胱癌细胞迁移和增殖抑制。
Cell Prolif. 2020 Feb;53(2):e12751. doi: 10.1111/cpr.12751. Epub 2020 Jan 23.
5
DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer.DNMT3B 沉默通过表观遗传促进 miR-34a 来抑制膀胱癌的迁移和侵袭。
Aging (Albany NY). 2020 Nov 20;12(23):23668-23683. doi: 10.18632/aging.103820.
6
Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382.穿心莲内酯通过减轻 DNMT3B 依赖性的肿瘤抑制基因 ZNF382 抑制来抑制胰腺癌的恶性程度。
Phytomedicine. 2024 Sep;132:155860. doi: 10.1016/j.phymed.2024.155860. Epub 2024 Jul 4.
7
The role of SOX18 in bladder cancer and its underlying mechanism in mediating cellular functions.SOX18 在膀胱癌中的作用及其在调节细胞功能中的潜在机制。
Life Sci. 2019 Sep 1;232:116614. doi: 10.1016/j.lfs.2019.116614. Epub 2019 Jun 28.
8
The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa expressions in bladder cancer tissues.膀胱癌组织中 DNA 甲基转移酶 3B（DNMT3B）与 miR 124-3pa 表达的关系。
Mol Biol Rep. 2023 Dec;50(12):10005-10013. doi: 10.1007/s11033-023-08818-2. Epub 2023 Oct 30.
9
The regulation of SOX7 and its tumor suppressive role in breast cancer.SOX7的调控及其在乳腺癌中的肿瘤抑制作用。
Am J Pathol. 2013 Nov;183(5):1645-1653. doi: 10.1016/j.ajpath.2013.07.025. Epub 2013 Sep 5.
10
METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.METTL3/YTHDF2 m6A 轴通过表观遗传抑制 RRAS 促进膀胱癌的恶性进展。
Oncol Rep. 2023 May;49(5). doi: 10.3892/or.2023.8531. Epub 2023 Mar 24.

引用本文的文献

1
M6A-modified BFSP1 induces aerobic glycolysis to promote liver cancer growth and metastasis through upregulating tropomodulin 4.m6A修饰的BFSP1通过上调原肌球蛋白4诱导有氧糖酵解，促进肝癌生长和转移。
Mol Biomed. 2025 Mar 18;6(1):17. doi: 10.1186/s43556-025-00256-9.
2
Epigenetic modifications in bladder cancer: crosstalk between DNA methylation and miRNAs.膀胱癌中的表观遗传修饰：DNA甲基化与微小RNA之间的相互作用
Front Immunol. 2025 Feb 5;16:1518144. doi: 10.3389/fimmu.2025.1518144. eCollection 2025.

本文引用的文献

1
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.NCCN 指南®洞察：膀胱癌，第 3.2024 版。
J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024.
2
circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA.环状KDM1A通过吸附miR-889-3p/CPEB3并稳定p53 mRNA来抑制膀胱癌进展。
iScience. 2024 Mar 29;27(4):109624. doi: 10.1016/j.isci.2024.109624. eCollection 2024 Apr 19.
3
Bladder cancer.膀胱癌。
Nat Rev Dis Primers. 2023 Oct 26;9(1):58. doi: 10.1038/s41572-023-00468-9.
4
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting.癌症生物学中的甲基转移酶样蛋白及其潜在的治疗靶点。
J Hematol Oncol. 2023 Aug 2;16(1):89. doi: 10.1186/s13045-023-01477-7.
5
Current best practice for bladder cancer: a narrative review of diagnostics and treatments.当前膀胱癌的最佳实践：诊断和治疗的叙述性综述。
Lancet. 2022 Nov 12;400(10364):1712-1721. doi: 10.1016/S0140-6736(22)01188-6. Epub 2022 Sep 26.
6
PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer.PHGDH 通过上调膀胱癌中的 SLC7A11 抑制铁死亡并促进恶性进展。
Int J Biol Sci. 2022 Aug 29;18(14):5459-5474. doi: 10.7150/ijbs.74546. eCollection 2022.
7
Cytoglobin has potent superoxide dismutase function.细胞血红素蛋白具有很强的超氧化物歧化酶功能。
Proc Natl Acad Sci U S A. 2021 Dec 28;118(52). doi: 10.1073/pnas.2105053118.
8
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
9
The role of globins in cardiovascular physiology.球蛋白在心血管生理学中的作用。
Physiol Rev. 2022 Apr 1;102(2):859-892. doi: 10.1152/physrev.00037.2020. Epub 2021 Sep 6.
10
Methylation multiplicity and its clinical values in cancer.甲基化多样性及其在癌症中的临床价值。
Expert Rev Mol Med. 2021 Mar 31;23:e2. doi: 10.1017/erm.2021.4.